Skip to main content

Specialty Pharmacy

  • Takeda, Ultragenyx partner to develop rare genetic disease treatments

    NOVATO, Calif. and OSAKA, Japan — Takeda on Tuesday announced a new partnership with Ultragenyx Pharmaceutical to develop and commercialize therapies for rare genetic diseases. 
     

  • Smart Messaging for Proactive Patient Engagement

    Value-based care is driving a number of positive trends within the retail pharmacy sector.

  • Diplomat closes TNH Specialty Pharmacy acquisition

    FLINT, Mich. — Diplomat Pharmacy on Thursday announced that it had completed its acquisition of Valley Campus Pharmacy, which does business as TNH Advanced Specialty Pharmacy providing individualized patient care in Van Nuys, Calif. 
     

  • IMS Institute study examines growth of global oncology market

  • Promius Pharma launches Sernivo Spray

    PRINCETON, N.J. — Dr. Reddy’s Laboratory subsidiary Promius Pharma on Wednesday announced the launch of its Sernivo Spray (betamethasone dipropionate). 
     
    The topical steroid is indicated to treat mild to moderate plaque psoriasis in patients older than 18 years of age. 
     

  • Diplomat to host first ‘Diplomat Dialogue’

    FLINT, Mich. — Diplomat Pharmacy on Wednesday announced its plan to host a video conversation — the first of its ‘Diplomat Dialogue’ conversations — in honor of National Cancer Survivors Day. “Diplomat Dialogue” events are conversations between patients and health care professionals focusing on a single patient in-depth. 
     

  • Drive DeVilbliss opens 4th DC due to increased DME demand

    PORT WASHINGTON, N.Y. – On June 1, Drive DeVilbiss Healthcare will open a fourth distribution center in Indianapolis in order to meet a growing demand for Drive DeVilbiss products, the company announced Tuesday.

    “This demonstrates our commitment to our customers,” stated Harvey Diamond, CEO Drive DeVilbiss. “Customers who are serviced by the new distribution center will have access to the entire Drive DeVilbiss product portfolio. We will continue to optimize our supply chain to provide better value and improved service levels to our customers.”

  • AbbVie, Biogen receive FDA approval for new MS treatment

    SILVER SPRING, Md. — The Food and Drug Administration has approved Biogen and AbbVie’s Zinbryta (daclizumab), the companies announced Tuesday. The drug is a once-daily self-administered injection indicated to treat relapsing forms of multiple sclerosis in patients who have had an inadequate response to two or more MS therapies. 
     
X
This ad will auto-close in 10 seconds